The Crimean-Congo Hemorrhagic Fever drugs in development market research report provides comprehensive information on the therapeutics under development for Crimean-Congo Hemorrhagic Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Crimean-Congo Hemorrhagic Fever. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Crimean-Congo Hemorrhagic Fever and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Crimean-Congo Hemorrhagic Fever by eight companies/universities/institutes. The top development phase for Crimean-Congo Hemorrhagic Fever is preclinical with five drugs in that stage. The Crimean-Congo Hemorrhagic Fever pipeline has seven drugs in development by companies and four by universities/ institutes. Some of the companies in the Crimean-Congo Hemorrhagic Fever pipeline products market are: University of Oxford, Mapp Biopharmaceutical and Erciyes University.
The key mechanisms of action in the Crimean-Congo Hemorrhagic Fever pipeline product include The Crimean-Congo Hemorrhagic Fever pipeline products include three routes of administration with the top ROA being Intramuscular and seven key molecule types in the Crimean-Congo Hemorrhagic Fever pipeline products market including Monoclonal Antibody, and Vaccine.
Crimean-Congo Hemorrhagic Fever overview
Crimean Congo hemorrhagic fever (CCHF) is a tick-borne zoonotic viral disease caused by CCHF virus of genus Nairovirus (family Bunyaviridae). It is a deadly hemorrhagic fever that is transmitted by bites from infected ticks (mainly of the Hyalomma genus) or by direct contact with blood or tissues of infected ticks, viraemic patients or viraemic livestock.
For a complete picture of Crimean-Congo Hemorrhagic Fever’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
